Offhand these data seem quite impressive. I'll await the actual data though in terms of absolute changes in LDL - the description of the topline efficacy data for the first trial was strange to me.
Potential negative sentiment today for ISIS and ALNY, but suggests their drugs could find success with this target too.
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com